1 CELL-FREE TUMOR DNA DOMINANT CLONE ALLELE FREQUENCY (DCAF) IS 2 ASSOCIATED WITH POOR OUTCOMES IN ADVANCED BILIARY CANCERS TREATED

3 WITH PLATINUM-BASED CHEMOTHERAPY

4 Running head: CELL-FREE TUMOR DNA IN ADVANCED BILIARY CANCERS

Pedro Luiz Serrano Uson Junior^{1, 10}, Umair Majeed², Jun Yin⁹, Gehan Botrus¹, Mohamad
Bassam Sonbol¹, Daniel H. Ahn¹, Jason S. Starr², Jeremy C Jones², Hani Babiker², Samantha
R Inabinett², Natasha Wylie², Ashton WR Boyle², Tanios S. Bekaii-Saab¹, Gregory J Gores³,
Rory Smoot⁴, Michael Barrett⁵, Bolni Nagalo^{1, 11}, Nathalie Meurice^{1,5}, Natalie Elliott¹, Joachim
Petit¹, Yumei Zhou¹, Mansi Arora¹, Chelsae Dumbauld¹, Oumar Barro¹, Alexander Baker¹,
James Bogenberger¹, Kenneth Buetow⁶, Aaron Mansfield⁴, Kabir Mody^{2*}, Mitesh J. Borad^{1, 5, 7,8 *}

- 11 1: Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ,
- 12 USA
- 13 2: Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL,
- 14 USA
- 15 3: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Rochester,
- 16 MN, USA
- 17 4: Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
- 18 5: Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA
- 19 6: Arizona State University, Tempe, AZ, USA
- 20 7: Department of Molecular Medicine, Rochester, MN, USA
- 21 8: Mayo Clinic Cancer Center, Phoenix, AZ, USA
- 9: Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA
- 23 10: Hospital Israelita Albert Einstein, São Paulo, Brazil
- 11: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- 25 *Equal contribution

```
26
```

- 27 Corresponding Author:
- 28 Mitesh J. Borad, M.D.
- 29 Email: <u>Borad.Mitesh@Mayo.edu</u>
- 30 Address: Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ
- 31

32 ACKNOWLEDGEMENTS

33 The Mayo Clinic Hepatobiliary SPORE (P50CA 210964) funded the statistical analysis for this project. This work was supported by the National Institute of Health (NIH) through a DP2 Award 34 CA195764 (to MJB); National Cancer Institute (NCI) K12 award CA090628 (to MJB), K01 award 35 36 CA234324 (to BN), SPORE Project Award 5P50CA210964-03 (to GJG and MJB), SPORE 37 Supplement Award 3P50CA210964-02S1 (to OB), Mayo Clinic Center for Individualized Medicine (CIM) Precision Cancer Therapeutics Program; and Mayo Clinic Cancer Center. The 38 39 funders had no role in study design, data collection and analysis, decision to publish or 40 preparation of the manuscript. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. 41

- 42
- 43
- 44
- 45
- -
- 46
- 47
- 48
- 49
- 50

52

53 ABSTRACT

54

PURPOSE: This investigation sough to evaluate the prognostic value of pre-treatment ctDNA in
 metastatic biliary tract cancers (BTC) treated with platinum based first-line chemotherapy
 treatment.

58

59 **METHODS:** We performed a retrospective analysis of 67 patients who underwent ctDNA testing 60 before platinum-based chemotherapy for first-line treatment for metastatic BTC. For analysis we 61 considered the detected gene with highest variant allele frequency (VAF) as the dominant clone 62 allele frequency (DCAF). Results of ctDNA analysis were correlated with patients' 63 demographics, progression-free survival (PFS) and overall survival (OS).

64

RESULTS: The median age of patients was 67 years (27-90). 54 (80.6%) of 67 patients 65 evaluated had intrahepatic cholangiocarcinoma; seven had extrahepatic cholangiocarcinoma 66 67 and six gallbladder cancers. 46 (68.6%) of the patients were treated with cisplatin plus gemcitabine, 16.4% of patients received gemcitabine and other platinum (carboplatin or 68 69 oxaliplatin) combinations while 15% of patients were treated on a clinical trial with gemcitabine 70 and cisplatin plus additional agents (CX4945, PEGPH20 or nab-paclitaxel). TP53, KRAS, 71 FGFR2, ARID1A, STK11 and IDH1 were the genes with highest frequency as DCAF. Median DCAF was 3% (0-97%). DCAF >3% was associated with worse OS (median OS: 10.8 vs. 18.8 72 73 months, p=0.032). Stratifying DCAF in guartiles, DCAF>10% was significantly related to worse 74 PFS (median PFS: 3 months, p=0.014) and worse OS (median OS: 7.0 months, p=0.001). Each 75 1% increase in ctDNA was associated with a hazard ratio of 13.1 in OS when adjusting for subtypes, metastatic sites, size of largest tumor, age, sex, and CA19-9. 76

77

CONCLUSION: DCAF at diagnosis of advanced BTC can stratify patients who have worse
 outcomes when treated with upfront platinum-based chemotherapy. Each increase in %ctDNA
 decrease survival probabilities.

81

82 **KEYWORDS:** Biliary tract cancers, cell-free tumor DNA, liquid biopsy, cholangiocarcinoma

83

84 INTRODUCTION

85

Biliary tract cancers (BTCs) include intrahepatic cholangiocarcinoma (IHC), gallbladder cancer (GBC) and extrahepatic cholangiocarcinoma (EHC) and ampulla of Vater cancers (AVC) [1]. BTC represents 3% of gastrointestinal malignancies with 11,980 cases expected to be diagnosed in 2021 [2, 3]. As BTC usually present at an advanced stage only 20% of these tumors are considered resectable [4]. In patients with unresectable disease the 5-year overall survival is about 4% [5].

The survival gain with first-line chemotherapy regimens in BTC is modest since most patients develop progressive disease with a median overall survival (OS) of less than a year [6]. This has generated interest in using next-generation tumor genomic profiling (NGS) and liquid tumor biopsy on peripheral blood to look for targetable genetic alterations [7, 8].

96 Circulating tumor DNA (ctDNA) has been shown to carry tumor-specific genetic or epigenetic alterations including point mutations, copy number variations, chromosomal rearrangements, 97 98 and DNA methylation. This ctDNA is released into the circulation after tumor cells undergo 99 apoptosis or necrosis [9]. Evaluation of ctDNA can identify patient specific tumoral genetic 100 alterations while allowing for serial monitoring of tumor genomes in a non-invasive and accurate 101 manner [8]. Therapeutically relevant alterations were seen in ctDNA in 55% of biliary tract 102 cancer patients [8]. Due to these findings the strategy is being used in the setting of advanced 103 disease for treatment selection [10]. Furthermore, it has also been used as an early marker of 104 response to treatment and to track mechanisms of acquired resistance [11].

In colon and breast cancer ctDNA has been used to predict response to treatment and prognosis in the adjuvant and neoadjuvant setting respectively [12, 13]. One marker of interest is variant allele frequency (VAF), which is the number of mutant molecules over total number of wild-type molecules at a specific location on the genome. Pairawan et.al showed that VAF is a surrogate marker of tumor burden and maximum VAF (VAFmax) correlated negatively with prognosis and survival in metastatic cancer [14].

111 In this study we hypothesized that the dominant clone allele frequency (DCAF) on ctDNA in 112 biliary tract cancer would be associated with overall survival (OS) and progression free survival

(PFS) and can serve as a surrogate of disease volume and severity. In addition, we looked at relationship of DCAF to treatment response with first-line platinum-based chemotherapy and clinical demographics.

116 MATERIALS AND METHODS

117 Patients

118

From July 2016 through June 2020, 67 patients with advanced BTC underwent ctDNA testing at diagnosis using an available assay [Guardant Health, Inc. (Redwood City, CA)]. All the patients received care at Mayo Clinic Cancer Center in Arizona and Florida. The analysis from this cohort was reviewed and approved by the Mayo Clinic institutional review board. Clinical and demographic information of all patients are included in **Table 1**.

124

125 **Comprehensive genomic testing in plasma**

126

127 Circulating tumor DNA was extracted from whole blood. ctDNA fragments, both leukocyte- and 128 tumor-derived, were simultaneously sequenced. The VAF was calculated as the proportion of 129 ctDNA harboring the variant in a background of wild type ctDNA. Analytical information, 130 bioinformatics analysis and Guardant360 database has been previously described [15, 16].

131

132 Outcomes

133

Assessments regarding response to therapy (complete response [CR], partial response [PR], 134 stable disease [SD], disease progression [PD]) were retrospectively collected by review of 135 patient's charts. Positive response to therapy was considered PR and CR by Response 136 137 Evaluation Criteria in Solid Tumors (RECIST). Disease control rate was determined based on 138 CR, PR, and SD. Progression-free survival (PFS) was determined by the time during treatment with chemotherapy and after without disease progression. Overall survival (OS) was 139 140 determined by the time of diagnosis of advanced disease till death or last day of follow up for patients on treatment and alive. 141

142

143 Statistical analysis

145 We summarized categorical data as frequency counts and percentages, and continuous 146 measures as means, standard deviations, medians, and ranges. Categorical variables were 147 compared using the chi-square test or Fisher's exact test. Continuous variables were compared using the one-way ANOVA test or Kruskal-Wallis test. Multivariate logistic regressions were 148 149 performed to assess the association of ctDNA with response rate and disease control rate with adjustment for disease subtype, age, sex, CA19-9, lesion size, and metastatic site. The 150 151 distributions of time-to-event outcomes were estimated using the Kaplan-Meier methods and compared between low versus high ctDNA dichotomized by the median dominant clone allele 152 153 frequency (i.e., low < 3% versus high >= 3% ctDNA) using the log-rank test. Hazard ratios (HRs) 154 and 95% confidence intervals (CIs) were estimated using a multivariate Cox model adjusting for disease subtype, age, sex, CA19-9, lesion size, and metastatic site. Sensitivity analysis were 155 156 conducted to explore either 3-quantiles (<= 33% percentile, 34-66% percentile, > 66% 157 percentile) or quartiles as the cutoffs in dominant clone allele frequency.

- 158
- 159 **RESULTS**

160

161 **Patient demographics**

162

A total of 67 patients were included in the analysis. 80.6% (54) had intrahepatic 163 164 cholangiocarcinoma, 10.4% (7) patients had extrahepatic cholangiocarcinoma and 9% (6) had gallbladder cancer. All patients included had ctDNA collected before the first-line chemotherapy 165 166 regimen for advanced disease. Median age of all patients was 67 y/o (27-90) and the majority 167 were female (62.6%). All patients were treated with platinum-based chemotherapy regimens as 168 first-line treatment. Most patients (68.6%) were treated with cisplatin plus gemcitabine, eleven 169 (16,4%) patients received gemcitabine plus other platinum (carboplatin or oxaliplatin) 170 combinations while ten (15%) patients were treated on a clinical trial with gemcitabine and cisplatin plus additional agents (CX4945, PEGPH20 or nab-paclitaxel). The median size of 171 172 largest lesion was 6 cm (2-19cm) and more than half (58.2%) had multiple metastatic sites 173 including liver and extrahepatic sites. Lungs, bones, lymph nodes and peritoneum were the sites with most extrahepatic metastasis identified. Other clinical information can be found on 174 175 Table 1.

Several potential targetable genes were detected with ctDNA including FGFR2, HER2, IDH, MET, EGFR, BRAF and KRAS. A higher prevalence of TP53 were observed among the three subtypes. Homologous recombinant repair genes were identified in IHC and EHC including ATM and BRCA2. Prevalence of all genomic alterations accordingly to primary tumor can be found on **Figure 1**.

181 TP53, KRAS, FGFR2, ARID1A, STK11 and IDH1 were the genes with highest variant allele 182 frequency as dominant clone (**Figure 2**). Most ERBB2 (HER-2) genomic alterations detected 183 were amplifications, identified in 4 patients. Other genes with detected amplifications included 184 KRAS, EGFR, BRAF, MET, CCNE1, CCND1, CCND2, MYC, FGFR1, FGFR2, CDK4, CDK6, 185 PIK3CA, AR. For analysis we considered the detected genomic alteration with the highest 186 variant allele frequency (VAF) as the dominant clone allele frequency (DCAF).

187

188 Dominant clone allele frequency and prognostic factors

189

One patient with no tumor genomic alteration detected was excluded from this analysis. The median dominant clone allele frequency (DCAF) was 3% (0-97%). DCAF >3% was associated with inferior PFS (median PFS: 4.7 vs. 7.7 months, p=0.087. **Supplementary figure 1**) and significantly worse OS (median OS: 10.8 vs. 18.8 months, p=0.032. **Figure 3**).

We further analyzed DCAF using either 3-quantiles or quartiles as the cutoffs. DCAF divided by 3 quantiles (Q1: ctDNA \leq 1%, Q2: ctDNA 1-7%, Q3: ctDNA \geq 7%) was significantly associated with PFS (p=0.022) (**Supplementary figure 2**) but not OS (p=0.065) (**Supplementary figure** 3). DCAF divided by quartiles (Q1: ctDNA \leq 0.6%, ctDNA Q2: 0.6-3%, ctDNA Q3: 3-10%, ctDNA Q4: \geq 10%) was significantly associated with PFS (p=0.014) (**Figure 4**) and OS (p=0.001) (**Figure 5**).

Each 1% increase in ctDNA is associated with a hazard ratio of 13.1 in OS when adjusting for primary tumor, size of the largest lesion, metastatic sites, sex, age, and CA19-9 (**Table 2**). No significant differences in response or disease control rate to chemotherapy was observed in patients with low or high ctDNA (**Supplementary figure 4 and 5**). No statistical significance was found between DCAF and the presence of potential actionable targets including FGFR2, IDH1/2, ERBB2 and KRAS (**Supplementary figure 6**).

206 The interaction between CA19-9 and DCAF were not statistically significant (OS: P_{interaction} =

207 0.12; PFS: P_{interaction} = 0.06). Although CCA patients with high DCAF and high CA19-9 (DFCA >=

3%, CA19-9 >= 100) had worst OS, no statistical significance was found for PFS (p=0.19) or OS

209 (p=0.13) (Supplementary figures 7 and 8).

210 **DISCUSSION**

211

212 In this study, we assessed whether the highest variant allele frequency detected by ctDNA, 213 namely DCAF, could be a prognostic factor in patients with advanced biliary tract cancer at 214 diagnosis. Based on the findings, patients with DCAF>3% at diagnosis had worse overall 215 survival when treated with upfront platinum-based chemotherapy. Furthermore, DCAF>10% 216 was significantly related to worse PFS and OS. However, no differences in response rate were 217 observed among patients with DCAF high or low. Moreover, ctDNA proved to be an independent factor related to overall survival in multivariate analysis. Collectively, these data 218 219 suggest a prognostic and not predictive role for DCAF in patients with advanced biliary tract 220 cancer undergoing platinum-based therapy.

The landscape of ctDNA genomic alterations of biliary tract cancers has already been previously described [8, 17]. Similarly, to our findings, these studies included more patients with IHC, and the genes with the highest detection with ctDNA included principally KRAS, TP53, FGFR2, IDH1 and ARID1A [8, 17]. In our cohort, we observed different patterns of prevalence, with ATM and MAP2K1 detected in extrahepatic cholangiocarcinoma and ERBB2, NF1 and PTEN in gallbladder cancer.

227 Variant allele frequency is related to outcomes, it is more prominent in metastatic disease and is 228 associated with tumor volume [14, 16, 18]. In metastatic pancreatic cancer, detectable ctDNA 229 and high VAF was associated with worse overall survival [18, 19, 20]. Prognostic significance 230 was observed in other solid tumors including colorectal cancer, breast cancer and prostate cancer [21-23]. Little is known about VAF and prognosis in biliary tract cancers. Lower values of 231 232 VAF were associated with prolonged progression-free survival in a cohort of 24 patients with 233 cholangiocarcinoma [18]. Considering the highest VAF value, we showed that the DCAF>3% is 234 related to numerically inferior PFS (but not statistically significant) and worse OS in patients with 235 biliary tract cancers treated with standard upfront platinum-based chemotherapy for advanced 236 disease. Interestingly, the DCAF was determined by multiple different genes among the cases,

including TP53, KRAS, FGFR2, ARID1A, STK11 and IDH1, suggesting as previously stated by
other colleagues that the highest VAF would be a surrogate of disease burden not related
specifically to the gene detected. In agreement with this, evaluating the presence of specific
genes of interest in the ctDNA overall analysis we did not found any association with DCAF and
possible targetable genes including FGFR2, ERBB2, IDH1 and KRAS.

242 Prognostic factors related to PFS and OS in advanced biliary tract cancers were evaluated from 243 the ABC-02 trial and an international dataset [24]. In this analysis, the authors evaluated 244 prognostic factors in a combined sample size of more than one thousand patients [24]. Although 245 the results suggest multiples factors in multivariate analysis including hemoglobin, gender and 246 neutrophils, receiver operator curve (ROC) analysis suggested that the model generated had a 247 limited prognostic value [24]. Even the primary tumor site was not significant, in contrast to the 248 findings of other groups [25]. After multiple efforts evaluating scores and factors to prognostication of advanced biliary tract cancers [26, 27, 28], the ability to predict prognosis 249 250 need improvement. In our analysis, the overall survival impact of ctDNA was observed after 251 stratifying with other possible prognostic factors including size of largest lesion, locally 252 advanced/metastatic designation, primary tumor location, metastatic sites, gender, CA 19-9 and 253 age. Evaluating ctDNA as a continuous variable, higher values are related to inferior survival probabilities. Based on the findings, ctDNA and DCAF could be a reliable easy to collect 254 255 prognostic instrument in prospective trials.

256 Considering the investigative field of ctDNA in biliary tract cancers, larger, multi-centered 257 prospective studies would be necessary to address the application of ctDNA in the multiple 258 disease assessment junctures, considering early diagnosis, minimal residual disease 259 assessment, monitoring in advanced stages during systemic treatment and assessment of 260 mutations that associate with resistance during treatment with targeted therapies. Evaluation of ctDNA and DCAF in metastatic disease would be a tool for genomic profiling in prospective 261 262 trials, can be a surrogate of disease volume and will assist in an adequate stratification of 263 patients with advanced biliary tract cancer in randomized studies.

Some limitations of this study include the number of patients, limited institution aspect, inherent limitations associated with a targeted gene panel and the retrospective nature of data collection. Furthermore, most of the patients included had tumor arising from the intrahepatic duct. This limitation is shared with studies in biliary tract cancers and efforts should be made to include patients with extrahepatic and gallbladder carcinomas in initiatives of genomic profiling and

ctDNA. Even with the limited number of patients, strong association of ctDNA and OS were observed. This study only evaluated patients treated with upfront chemotherapy. Although this is the standard of care to date, multiple trials are evaluating targeted treatments including FGFR2 inhibitors in the first-line therapy for advanced disease and it would be unclear if upfront tyrosine kinase inhibitors would alter the results. On the other hand, as stated before, the presence of targetable genes had no association with DCAF results and impact of ctDNA on overall survival.

275 CONCLUSION

ctDNA is a powerful prognostic tool in advanced biliary tract cancers. DCAF at diagnosis of advanced disease who would receive platinum based systemic therapy identifies patients with worse prognosis. ctDNA should be evaluated in prospective trials as a stratification factor for advanced disease.

280

281 **REFERENCES**

- 282 1. de Groen, P.C., et al., Biliary tract cancers. N Engl J Med, 1999. 341(18): p. 1368-78.
- Charbel, H. and F.H. Al-Kawas, Cholangiocarcinoma: epidemiology, risk factors,
 pathogenesis, and diagnosis. Curr Gastroenterol Rep, 2011. 13(2): p. 182-7.
- Siegel, R.L., et al., Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 2021.
 71(1): p. 7-33.
- Shroff, R.T., et al., Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical
 Practice Guideline. J Clin Oncol, 2019. 37(12): p. 1015-1027.
- 5. Farley, D.R., A.L. Weaver, and D.M. Nagorney, "Natural history" of unresected
 cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc,
 1995. 70(5): p. 425-9.
- Valle, J., et al., Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N
 Engl J Med, 2010. 362(14): p. 1273-81.
- Valle, J.W., et al., New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer
 Discov, 2017. 7(9): p. 943-962.
- Mody, K., et al., Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.
 JCO Precision Oncology, 2019(3): p. 1-9.
- Lu, L., J. Bi, and L. Bao, Genetic profiling of cancer with circulating tumor DNA analysis.
 J Genet Genomics, 2018. 45(2): p. 79-85.

10. Hovelson, D.H., et al., Rapid, ultra low coverage copy number profiling of cell-free DNA
 as a precision oncology screening strategy. Oncotarget, 2017. 8(52): p. 89848-89866.

- 11. Goyal, L., et al., Polyclonal Secondary FGFR2 Mutations Drive Acquired
 Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive
 Cholangiocarcinoma. Cancer Discovery, 2017. 7(3): p. 252-263.
- 12. Reece, M., et al., The Use of Circulating Tumor DNA to Monitor and Predict Response to
 Treatment in Colorectal Cancer. Frontiers in genetics, 2019. 10: p. 1118-1118.
- 13. Li, S., et al., Circulating Tumor DNA Predicts the Response and Prognosis in Patients
 With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. JCO Precision
 Oncology, 2020(4): p. 244-257.
- 14. Pairawan, S., et al., Cell-free Circulating Tumor DNA Variant Allele Frequency
 Associates with Survival in Metastatic Cancer. Clin Cancer Res, 2020. 26(8): p. 1924 1931.
- 15. Lanman, Richard B., et al. "Analytical and clinical validation of a digital sequencing panel
 for quantitative, highly accurate evaluation of cell-free circulating tumor DNA." *PloS one* 10.10 (2015): e0140712.
- 316 16. Botrus, Gehan, et al. "Circulating Tumor DNA-Based Testing and Actionable Findings in
 317 Patients with Advanced and Metastatic Pancreatic Adenocarcinoma." *The* 318 *Oncologist* (2021).
- 319 17. Okamura, Ryosuke, et al. "Comprehensive genomic landscape and precision therapeutic
 320 approach in biliary tract cancers." *International journal of cancer* 148.3 (2021): 702-712.
- 18. Strijker, Marin, et al. "Circulating tumor DNA quantity is related to tumor volume and both
 predict survival in metastatic pancreatic ductal adenocarcinoma." *International journal of cancer* 146.5 (2020): 1445-1456.
- 19. Bernard, Vincent, et al. "Circulating nucleic acids are associated with outcomes of
 patients with pancreatic cancer." *Gastroenterology* 156.1 (2019): 108-118.
- 20. Patel, Hitendra, et al. "Clinical correlates of blood-derived circulating tumor DNA in
 pancreatic cancer." *Journal of hematology & oncology* 12.1 (2019): 1-12.

21. Dasari, Arvind, et al. "ctDNA applications and integration in colorectal cancer: An NCI
 Colon and Rectal–Anal Task Forces whitepaper." *Nature Reviews Clinical Oncology* 17.12 (2020): 757-770.

- 22. Cullinane, Carolyn, et al. "Association of Circulating Tumor DNA With Disease-Free
 Survival in Breast Cancer: A Systematic Review and Meta-analysis." *JAMA network open* 3.11 (2020): e2026921-e2026921.
- 334 23. Goodall, Jane, et al. "Circulating tumor DNA (ctDNA) dynamics associate with treatment
 335 response and radiological progression-free survival (rPFS): Analyses from a randomized
 336 phase II trial in metastatic castration-resistant prostate cancer (mCRPC)." JCO (2020):
 337 5508-5508.
- 338 24. Bridgewater, John, et al. "Prognostic factors for progression-free and overall survival in
 advanced biliary tract cancer." *Annals of Oncology* 27.1 (2016): 134-140.
- 25. Peixoto RDA, Renouf D, Lim H. A population based analysis of prognostic factors in
 advanced biliary tract cancer. J Gastrointest Oncol 2014; 5: 428–432.
- 26. Park, Hyung Soon, et al. "Prognostic factors and scoring model for survival in metastatic
 biliary tract cancer." *Cancer research and treatment: official journal of Korean Cancer*Association 49.4 (2017): 1127.
- 345 27. Salati, Massimiliano, et al. "The prognostic nutritional index predicts survival and
 346 response to first-line chemotherapy in advanced biliary cancer." *Liver International* 40.3
 347 (2020): 704-711.
- 28. Kim, Bum Jun, et al. "Prognostic factors in patients with advanced biliary tract cancer
 treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740
 patients." *Cancer chemotherapy and pharmacology* 80.1 (2017): 209-215.
- 351
- 352
- 353
- 354
- 355

- 356 357 358 359 360 361 362 Tables and figures 363 364 **Table 1: Demographic characteristics** 365
 Table 2: Multivariate analysis for overall survival
 366 Figure 1: Prevalence of genomic alterations accordingly to primary tumor 367 Figure 2: Variant allele frequency of detected genes 368 Figure 3: Overall survival Kaplan-Meier curve by DCAF>3% Figure 4: Progression-free survival Kaplan-Meier curve by ctDNA 369 Figure 5: Overall survival Kaplan-Meier curve by ctDNA 370 371 372 373 Supplementary figure 1: Progression-free survival and DCAF>3% 374 Supplementary figure 2: Progression-free survival and DCAF guartiles 375 Supplementary figure 3: Overall survival and DCAF quartiles 376 Supplementary figure 4: ctDNA Response vs. Non–Response. p = 0.2678 Supplementary figure 5: ctDNA Disease Control vs. Disease progression. p = 0.0843 377 Supplementary figure 6: ctDNA by Group. p = 0.1373 378 379 Supplementary figure 7: CA19-9 and DCAF impact on PFS Supplementary figure 8: CA19-9 and DCAF impact on OS 380
- 381

382	
383	
384	
385	
386	
387	
388	
389	Table 1: Demographic characteristics
390	

	Overall (N=67)
Age at diagnosis, years	
Median (range)	67 (27, 90)
Sex	
Male	25 (37.4%)
Female	42 (62.6%)
Diagnosis	
Extrahepatic cholangiocarcinoma	7 (10.4%)
Gallbladder carcinoma	6 (9.0%)
Intrahepatic cholangiocarcinoma	54 (80.6%)
Grouping by genomic alterations	
FGFR2	9 (13.4%)
ERBB2	6 (9.0%)
IDH1	11 (16.4%)
KRAS	9 (13.4%)
Not detectable	1 (1.5%)
Other (TP53, CDKN2A, BRAF, STK11, APC, RET, ARID1A, EGFR, ATM)	31 (46.3%)
Treatment	
Gemcitabine + Cisplatin	46 (68.6%)
Gemcitabine + Cisplatin + CX-4945	6 (8.95%)
Gemcitabine + Oxaliplatin	6 (8.95%)
Gemcitabine + Carboplatin	5 (7.5%)
Gemcitabine + Cisplatin + Nab-paclitaxel	3 (4.5%)

	Gemcitabine + Cisplatin + PEGPH20	1 (1.5%)
	Size of largest lesion (cm)	, , ,
	Median (range)	6 (2-19)
	Metastatic sites	
	Liver	24 (35.8%)
	Extrahepatic only (ex. lung, bones, peritoneum, lymph nodes)	4 (6%)
	Liver + extrahepatic	39 (58.2%)
	Pre-Treatment CA19-9 Level (U/mL)	
	Median (range)	103 (1-103198)
	Pre-Treatment Maximum Mutant Allele Frequency (%)	
	Mean Cl	10 (6, 14)
	Median (range)	3 (0 – 94)
	Q1, Q3	1, 10
	Tumor response (partial response + complete response)	
	No	34 (57.6%)
	Yes	25 (42.4%)
	Disease Control (partial response + complete response + stable disease)	
	No	21 (35.6%)
	Yes	38 (64.4%)
	Progression-free survival events	
	No	31 (46.3%)
	Yes	36 (53.7%)
	Overall survival events	
	No	28 (41.8%)
201	Yes	39 (58.2%)
291		
392		
393		
394		
395		
396		
397		

405 Table 2: Multivariate analysis for overall survival

	Hazard	95%CI	P value
	Ratio		
Location of primary: non-IHC vs. IHC	1.54	[0.46 , 5.21]	0.484825
Age at diagnosis, 10yrs	1.18	[0.83 , 1.67]	0.359703
Pre-Treatment CA19-9 Level (>=100 U/mL)	2.08	[0.96 , 4.53]	0.063824
ctDNA (%)	13.07	[1.2 , 142.32]	0.034866
Sex	1.24	[0.57 , 2.72]	0.588142
Lesion Size	1.02	[0.92 , 1.13]	0.762273
Met Site: Extrahepatic (Ref: Liver)	0.66	[0.08 , 5.47]	0.700660
Met Site: Liver + Extrahepatic (Ref: Liver)	1.09	[0.49 , 2.43]	0.831125

408	Legend: IHC: intrahepatic cholangiocarcinoma
409	
410	
411	
412	
413	
414	
415	
416	
417	
418	







Figure 2: Variant allele frequency of detected genes



473 Figure 3: Overall survival Kaplan-Meier curve by DCAF>3%









490 Figure 5: Overall survival Kaplan-Meier curve by groups

medRxiv preprint doi: https://doi.org/10.1101/2021.11.01.21265773; this version posted November 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.